Abstract |
The combination of lenalidomide plus dexamethasone (RD) is very effective for patients with relapsed/ refractory myeloma. However, the effect of RD on bone metabolism has not been previously evaluated in these patients. To address this issue, we initially performed a retrospective study in 106 consecutive patients with relapsed or refractory myeloma who received RD. We measured the following bone indices on Cycle 1/Day 1 and then on Cycles 3 and 6/Day 28: dickkopf-1 (Dkk-1), sRANKL, osteoprotegerin (OPG), bone resorption markers ( C-telopeptide of collagen type-I, CTX and TRACP-5b) and bone formation markers (bone-specific alkaline phosphatase-bALP and osteocalcin). RD produced a reduction of CTX only in responders, with no effect on bone formation. To validate these results, we then evaluated prospectively 99 patients who received either RD (n550) or VRD ( bortezomib + RD, n549). RD reduced CTX, mainly in responders but showed no effect on bone formation, confirming the result of the retrospective study. However, the addition of bortezomib to RD (VRD arm) reduced Dkk-1, sRANKL/OPG, and CTX, while it increased bALP and OC after six cycles of therapy. These changes were irrespective of treatment response, which was similar between treatment arms. No skeletal-related events were observed in the VRD arm while two, nonresponding patients treated with RD developed a vertebral fracture. We conclude that RD reduces bone resorption only in responding patients with relapsed/refractory myeloma but has no effect on bone formation. Combination with bortezomib, which enhances bone formation, seems to be preferred for the management of myeloma patients with osteolytic disease.
|
Authors | Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Eirini Katodritou, Athanasios Papatheodorou, Anastasia Pouli, Marie-Christine Kyrtsonis, Eurydiki Michalis, Xenophon Papanikolaou, Maria Gkotzamanidou, Efstathios Koulieris, Maria Gavriatopoulou, Konstantinos Zervas, Meletios A Dimopoulos, Greek Myeloma Study Group |
Journal | American journal of hematology
(Am J Hematol)
Vol. 89
Issue 1
Pg. 34-40
(Jan 2014)
ISSN: 1096-8652 [Electronic] United States |
PMID | 23983166
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers
- Thalidomide
- Dexamethasone
- Lenalidomide
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology, therapeutic use)
- Biomarkers
(metabolism)
- Bone Remodeling
(drug effects)
- Bone Resorption
(drug therapy, etiology, metabolism)
- Dexamethasone
(administration & dosage)
- Female
- Greece
- Humans
- Lenalidomide
- Male
- Middle Aged
- Multiple Myeloma
(complications, drug therapy, mortality, pathology)
- Neoplasm Grading
- Neoplasm Staging
- Osteogenesis
(drug effects)
- Recurrence
- Retrospective Studies
- Thalidomide
(administration & dosage, analogs & derivatives)
- Treatment Outcome
|